El-Gendy, Nashwa published the artcileDry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent, Quality Control of 117-96-4, the main research area is powder aerosol diatrizoate nanoparticle agglomerate lung contrast computed tomog.
Aerosolized contrast agents may improve the resolution of biomedical imaging modalities and enable more accurate diagnosis of lung diseases. Many iodinated compounds, such as diatrizoic acid, have been shown to be safe and useful for radiog. examination of the airways. Formulations of such compounds must be improved in order to allow imaging of the smallest airways. Here, diatrizoic acid nanoparticle agglomerates were created by assembling nanoparticles into inhalable microparticles that may augment deposition in the lung periphery. Nanoparticle agglomerates were fully characterized and safety was determined in vivo. After dry powder insufflation to rats, no acute alveolar tissue damage was observed 2 h post-dose. Diatrizoic acid nanoparticle agglomerates possess the characteristics of an efficient and safe inhalable lung contrast agent.
International Journal of Pharmaceutics published new progress about Biocompatibility. 117-96-4 belongs to class isoquinoline, name is Diatrizoic Acid, and the molecular formula is C11H9I3N2O4, Quality Control of 117-96-4.
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem